​pdf] 10 Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R,

​pdf] 10. Altekruse SF, Kosary CL, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb MS-275 DG, Edwards BK: SEER Cancer Statistics Review, 1975–2007. [http://​seer.​cancer.​gov/​csr/​1975_​2007/​]

In Edited by: Bethesda, MD. National Cancer Institute; 11. Hirschowitz E, Foody T, Hidalgo G, Yannelli J: Immunization of NSCLC patients with antigen-pulsed immature autologous dendritic cells. Lung Cancer 2007, 57:365–372.PubMedCrossRef 12. Hirschowitz EA: Autologous Dendritic Cell Vaccines for Non-Small-Cell Lung Cancer. Journal of Clinical Oncology 2004, 22:2808–2815.PubMedCrossRef 13. Avigan DE, Vasir B, George DJ, Oh WK, Atkins MB, McDermott DF, Kantoff Evofosfamide research buy PW, Figlin RA, Vasconcelles MJ, Xu Y, Kufe D, Bukowski RM: Phase I/II study of vaccination with electrofused allogeneic dendritic cells/autologous tumor-derived cells in patients with stage IV renal cell carcinoma. J Immunother 2007, 30:749–761.PubMedCrossRef 14. Um S, Choi YJ, Shin H, Son CH, Park Y, Roh MS, Kim YS, Kim YD, Lee S, Jung MH, Lee MK, Son C, Choi PJ, Chung J, Kang C, Lee E: Phase I study of autologous dendritic cell tumor vaccine in patients with non-small cell lung cancer. Lung Cancer 2010, 70:188–194.PubMedCrossRef 15. Berntsen A, Trepiakas R, Wenandy L, Geertsen PF, thor Straten P, Andersen MH, Pedersen AE, Claesson MH, Lorentzen T, Johansen JS,

Svane IM: Therapeutic dendritic cell vaccination of patients with Blasticidin S metastatic renal cell carcinoma: a clinical phase 1/2 trial. J Immunother 2008, 31:771–780.PubMedCrossRef 16. Gowans EJ, Roberts S, Jones K, Dinatale I, Latour PA, Chua B, Eriksson EMY, Chin R, Li S, Wall DM, Sparrow RL, Moloney J, Loudovaris M, Ffrench R, Prince HM, Hart D, Zeng W, Torresi J, Brown LE, Jackson DC: A phase tetracosactide I clinical trial of dendritic cell immunotherapy in HCV-infected individuals. J Hepatol 2010, 53:599–607.PubMedCrossRef

17. McNeel DG, Dunphy EJ, Davies JG, Frye TP, Johnson LE, Staab MJ, Horvath DL, Straus J, Alberti D, Marnocha R, Liu G, Eickhoff JC, Wilding G: Safety and Immunological Efficacy of a DNA Vaccine Encoding Prostatic Acid Phosphatase in Patients With Stage D0 Prostate Cancer. Journal of Clinical Oncology 2009, 27:4047–4054.PubMedCrossRef Competing interests The authors declare that they have no competing interests. Authors’ contributions STS and LZ conceived the design of the study, participated in data analysis and were in charge of its coordination. JV and HNH processed the tumor tissue and performed the immunohistochemistry. ASB and MWP cared for the patients during the conventional treatment. MWP and SCOG cared for the patients during the immunotherapy, participated in data analysis, performed data interpretation and drafted the manuscript. MTA conducted the laboratory procedures to produce the DC vaccine, supported by SCOG. All authors read and approved the final manuscript.

Related posts:

  1. Stem Cells 2008,26(6):1414–1424 PubMedCrossRef 12 Chung LW, Base
  2. The intrinsic resistance of uveal melanoma to conventional system
  3. J Immunol Methods 2005, 298: 61–72 PubMedCrossRef 19 Lin W, Vosk
  4. PP, MLF and AS coordinated the study VP, DD, CG, MLF collected d
  5. Br J Cance 1998, 77:1799–1805 CrossRef 30 Westermarck J, Kähäri
This entry was posted in Antibody. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *

*

You may use these HTML tags and attributes: <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <strike> <strong>